CPIX Stock Overview
A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cumberland Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.57 |
| 52 Week High | US$2.36 |
| 52 Week Low | US$1.42 |
| Beta | 0.18 |
| 1 Month Change | -3.09% |
| 3 Month Change | -28.96% |
| 1 Year Change | -3.68% |
| 3 Year Change | -45.10% |
| 5 Year Change | -75.28% |
| Change since IPO | -90.67% |
Recent News & Updates
Recent updates
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Mar 07
Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares
Jan 09Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S
Oct 02Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Aug 10Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Mar 18Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Nov 02Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Jul 20Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Apr 15Checking In On Cumberland Pharmaceuticals
Jan 04Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?
Nov 09We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation
Apr 21Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?
Feb 13One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts
Nov 19
Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 11Shareholder Returns
| CPIX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.7% | 1.9% | 1.2% |
| 1Y | -3.7% | 16.7% | 27.7% |
Return vs Industry: CPIX underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: CPIX underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| CPIX volatility | |
|---|---|
| CPIX Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CPIX's share price has been volatile over the past 3 months.
Volatility Over Time: CPIX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 91 | A. Kazimi | www.cumberlandpharma.com |
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.
Cumberland Pharmaceuticals Inc. Fundamentals Summary
| CPIX fundamental statistics | |
|---|---|
| Market cap | US$23.36m |
| Earnings (TTM) | -US$8.42m |
| Revenue (TTM) | US$38.83m |
0.6x
P/S Ratio-2.6x
P/E RatioIs CPIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPIX income statement (TTM) | |
|---|---|
| Revenue | US$38.83m |
| Cost of Revenue | US$6.39m |
| Gross Profit | US$32.43m |
| Other Expenses | US$40.85m |
| Earnings | -US$8.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 83.54% |
| Net Profit Margin | -21.68% |
| Debt/Equity Ratio | 59.2% |
How did CPIX perform over the long term?
See historical performance and comparison